RJA
SWTX

Raymond James & Associates’s SpringWorks Therapeutics SWTX Stock Holding History

Raymond James & Associates’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$506K Buy
15,792
+5,371
+52% +$201K ﹤0.01% 3106
2024
Q2 		$393K Buy
+10,421
New +$439K ﹤0.01% 3216
2021
Q3 		– Sell
-3,110
Closed -$256K – 4253
2021
Q2 		$256K Buy
+3,110
New +$236K ﹤0.01% 3542

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Raymond James & Associates's SWTX Position: Q3 2024 in Review

Raymond James & Associates increased its SpringWorks Therapeutics (SWTX) stake by 52% in Q3 2024, buying an estimated $201K and bringing the position to 15,792 shares worth $506K. The position accounts for ﹤0.01% of the portfolio, ranked #3106.

Raymond James & Associates first reported a position in SWTX in Q2 2021 and has held it in 3 quarters since. 226 funds tracked by Wall St. Rank hold SWTX as of Q3 2024.

  • Raymond James & Associates held 15,792 shares of SpringWorks Therapeutics worth $506K as of Q3 2024.
  • Raymond James & Associates bought 5,371 SpringWorks Therapeutics shares in Q3 2024, an estimated $201K.
  • SpringWorks Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3106 holding.
  • Raymond James & Associates first reported a position in SpringWorks Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • 226 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.